riluzole has been researched along with Adult Spinal Muscular Atrophy in 8 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fourteen patients were enrolled in an open-label, nonrandomized and repeat-dose pharmacokinetic study." | 2.76 | Riluzole pharmacokinetics in young patients with spinal muscular atrophy. ( Abbara, C; Barois, A; Diquet, B; Estournet, B; Lacomblez, L; Lehmann, B; Lelièvre, B; Ouslimani, A; Viollet, L, 2011) |
| "Severe spinal muscular atrophy (SMA) (Werdnig-Hoffmann disease, acute SMA, and SMA I) is a disease of the motor neuron characterized by onset before 6 months of age, failure ever to achieve sitting without support, and a life expectancy of 2 years or less." | 2.71 | A phase 1 trial of riluzole in spinal muscular atrophy. ( Iannaccone, ST; Russman, BS; Samaha, FJ, 2003) |
| "The first clinical trials in spinal muscular atrophy are currently underway." | 2.40 | Carrell-Krusen Symposium invited lecture. Clinical trials in motor neuron diseases. ( Miller, RG, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dimitriadi, M | 1 |
| Kye, MJ | 1 |
| Kalloo, G | 1 |
| Yersak, JM | 1 |
| Sahin, M | 1 |
| Hart, AC | 1 |
| Orrell, RW | 1 |
| Abbara, C | 1 |
| Estournet, B | 1 |
| Lacomblez, L | 1 |
| Lelièvre, B | 1 |
| Ouslimani, A | 1 |
| Lehmann, B | 1 |
| Viollet, L | 1 |
| Barois, A | 1 |
| Diquet, B | 1 |
| Cachia, D | 1 |
| Izzy, S | 1 |
| Ionete, C | 1 |
| Salameh, J | 1 |
| Pascuzzi, RM | 1 |
| Haddad, H | 1 |
| Cifuentes-Diaz, C | 1 |
| Miroglio, A | 1 |
| Roblot, N | 1 |
| Joshi, V | 1 |
| Melki, J | 1 |
| Russman, BS | 1 |
| Iannaccone, ST | 1 |
| Samaha, FJ | 1 |
| Miller, RG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Investigation of the Efficacy in Childhood Obsessive-Compulsive Disorder of Riluzole: An Antiglutamatergic Agent[NCT00251303] | Phase 2 | 78 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CY-BOCS is a 0-40 point scale of obsessive-compulsive symptom severity, higher number indicates more severe obsessive-compulsive symptoms. Comparison of 12 weeks scores for placebo and riluzole groups. (NCT00251303)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Riluzole | 21.72 |
| Placebo | 23.30 |
(NCT00251303)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| Riluzole | 3 |
| Placebo | 4 |
3 reviews available for riluzole and Adult Spinal Muscular Atrophy
| Article | Year |
|---|---|
Motor neuron disease: systematic reviews of treatment for ALS and SMA.
Topics: Amyotrophic Lateral Sclerosis; Databases as Topic; Humans; Motor Neuron Disease; Muscular Atrophy, S | 2010 |
ALS, motor neuron disease, and related disorders: a personal approach to diagnosis and management.
Topics: Adolescent; Adult; Animals; Case Management; Combined Modality Therapy; Creatine; Diagnosis, Differe | 2002 |
Carrell-Krusen Symposium invited lecture. Clinical trials in motor neuron diseases.
Topics: Acetates; Adolescent; Adult; Amines; Amyotrophic Lateral Sclerosis; Animals; Brain-Derived Neurotrop | 1999 |
2 trials available for riluzole and Adult Spinal Muscular Atrophy
| Article | Year |
|---|---|
Riluzole pharmacokinetics in young patients with spinal muscular atrophy.
Topics: Adolescent; Area Under Curve; Child; Dose-Response Relationship, Drug; Female; Humans; Male; Models, | 2011 |
A phase 1 trial of riluzole in spinal muscular atrophy.
Topics: Age of Onset; Child; Child, Preschool; Excitatory Amino Acid Antagonists; Humans; Infant; Infant, Ne | 2003 |
3 other studies available for riluzole and Adult Spinal Muscular Atrophy
| Article | Year |
|---|---|
The neuroprotective drug riluzole acts via small conductance Ca2+-activated K+ channels to ameliorate defects in spinal muscular atrophy models.
Topics: Animals; Axons; Caenorhabditis elegans; Cells, Cultured; Disease Models, Animal; Gene Knockdown Tech | 2013 |
Brachial amyotrophic diplegia in the setting of complete HIV viral load suppression.
Topics: Antiretroviral Therapy, Highly Active; Arm; HIV Infections; Humans; Male; Middle Aged; Muscle Weakne | 2012 |
Riluzole attenuates spinal muscular atrophy disease progression in a mouse model.
Topics: Animals; Axons; Cyclic AMP Response Element-Binding Protein; Cytoskeleton; Disease Progression; Gene | 2003 |